REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension

Part of paid clinical trials in Oakland, California.

Sponsor: Kaiser Permanente
Study ID: NCT07780500
Status: Recruiting

Apply to this trial

Conditions

Aldosterone Disorder
Cardiovascular Disease (CVD)
Hypertension

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

observational study — OTHER
Participants are not assigned an intervention

Study Details

The goal of the REFOCUS-HTN US-WEST program is to gain a better understanding of the role of a hormone called aldosterone in the development of hypertension. The SCALED sub-study is an observational cohort study that will enroll from REFOCUS-HTN cohort for prospective data collection.

Key Dates

First listed: Aug 21, 2026
Start date: Aug 20, 2026
Status verified: Jul 2026
Primary completion: Mar 31, 2028
Completion: Mar 31, 2029

Study Design

Enrollment: 500 participants (estimated)

Arms

Arm: SCALED Cohort
The SCALED Cohort will include \~500 participants from the REFOCUS-HTN Cohort who are KPNC health plan members aged 18 years or older with established hypertension diagnosed within the past 18 months prior to screening.